Entities

Clinical-stage nanomedicine company developing in-vitro diagnostics based on tethered enzymes attached to silica nanoparticles. A Cornell University spinout, its lead NSE-FAST test measures neuron-specific enolase activity to aid diagnosis of acute neurological injury, including ischemic stroke. The test remains in clinical development.

Medical-robotics company developing the IVY vascular-access platform, combining imaging, AI and robotics to automate difficult intravenous catheter placement. The system remains under development and is not available for sale.

Neurotechnology company developing personalized cervical spinal-cord stimulation to restore arm and hand movement after stroke. Its approach uses implanted electrodes and a pulse generator to stimulate movement-related spinal circuits and is being developed through clinical research.

Auticon provides technology consulting, AI, data analytics and software services through teams that employ autistic professionals.

BioROSA Technologies develops blood-based diagnostic tests intended to detect autism early using metabolic biomarkers.

Bluebird Kids Health operates pediatric clinics and value-based care programs that expand access for children covered by Medicaid and CHIP.

San Diego healthcare company co-founded by Suzanne Goh and Neil Hattangadi in 2017, providing coordinated care for children with autism and other neurodevelopmental conditions. Its model combines medical and neurological evaluation, behavioral therapies, developmental therapies and family support across clinics, homes and telehealth. The Cortica Innovation Network conducts clinical outcomes research and evaluates diagnostics, therapeutics and care technologies; its Axon software supports the clinical care model. It is relevant to neuroscience and technology-enabled healthcare. Specific clinical outcome claims remain attributed to the company and its studies. This clinical provider is separate from Israeli computer-vision business Cortica at cortica.ai and from EEG-services company CortiCare at corticare.com.

Eleplan provides AI-assisted care planning and information sharing for families and teams supporting people with complex health needs.

Floreo develops virtual-reality programs that teach social, communication and everyday skills to people with autism and related conditions.

Imagine Pediatrics provides round-the-clock virtual and in-home medical, behavioral and social care for children with complex health needs.

Joshin provides employers and families with disability and neurodiversity support through care navigation, coaching, accommodations assistance and digital programs. RethinkFirst acquired the company in August 2025 and integrated its services into RethinkCare.

MARAbio develops blood tests that identify maternal autoantibodies associated with a subtype of autism, supporting risk assessment and early intervention.

SpectrumAi provides clinical documentation and analytics software for applied behavior analysis and autism therapy providers.

Suggestic builds and operates custom enterprise AI systems on a private foundation of data, governance, model orchestration and compliance controls. Its platform grew from personalized health technology and now serves health, wellness, insurance, consumer goods and dental businesses.

Unison Therapy Services provides school-based and community-based speech, behavioral, occupational, physical and psychological therapies for children.

Vertero Therapeutics, formerly Axial Therapeutics, develops oral medicines that target peripheral drivers of neurodegenerative diseases, including Parkinson’s disease.

Yamo Pharmaceuticals develops L1-79, a medicine intended to treat the core symptoms of autism spectrum disorder.

Juvena Therapeutics board observer representing MAK Capital; also serves on MARAbio's board. Has investment, corporate development and legal experience.

Augmental makes the MouthPad, a tongue-operated interface that lets people control computers and other devices without using their hands.

Autism Impact Fund invests in healthcare technology, diagnostics, therapeutics and care services for autism, neurodevelopmental disorders, mental health and complex chronic conditions. Its portfolio includes AI-assisted care coordination, behavioral-health software and biotechnology.

Develops oral small-molecule medicines that enhance KCC2, a neuronal chloride transporter essential for inhibitory signaling in the brain. Its lead investigational drug, AXN-027, is in clinical development for epilepsy and pain. The company’s discovery platform also supports medicines for other neurological, psychiatric and neurodevelopmental disorders.

Cyllene Therapeutics, formerly EG 427, develops targeted DNA medicines for chronic neurological conditions, including neurogenic bladder dysfunction.

NervGen Pharma develops neuroreparative medicines intended to restore nervous-system function after spinal cord injury and other neurological damage.

Sania Therapeutics develops gene therapies that selectively target dysfunctional neural circuits to treat neurological disease.

ViaNautis develops polymer nanovesicles that deliver genetic medicines to selected cells, including targets in the brain and spinal cord.

Neurorehabilitation researcher and Shepherd Center research leader; also serves on the SCI Ventures board.

SV Health Investors venture partner and ViaNautis chief scientific officer, with immunology and drug discovery experience; previously chief scientific officer at Mestag Therapeutics, Enara Bio and TRexBio.

Neurosurgeon and biomedical-device researcher at the University of Calgary, with training in biomedical engineering and cerebrovascular surgery.

Calgary neurosurgeon specializing in brain aneurysms and stroke; co-founded Fluid Biomed with Alim Mitha.

Akita developed tools for observing API endpoints and understanding application behavior.

American Supercritical develops modular systems that convert waste heat into electricity using supercritical carbon dioxide.

Atropos Group develops autonomous aircraft for defense logistics and commercial cargo. CHAOS Industries acquired the company in July 2026.

Bluesky optimizes cloud data workloads and infrastructure spending.

Firestorm Labs develops modular unmanned aircraft and distributed manufacturing systems for defense.

LeapYear developed technology for privacy-preserving analysis of sensitive data.

MATERIAL develops additive manufacturing technology that prints batteries in custom shapes.

Monad provides data pipelines that collect and organize information from cybersecurity tools.

Orbital Operations develops high-thrust spacecraft for orbital mobility and space infrastructure missions.

Recursive Superintelligence develops AI systems designed to improve their own capabilities through recursive learning.

Super Powers Mobility develops electric off-road utility vehicles.

Tarly develops AI software to support defensible government acquisition and procurement decisions.

Tectonic develops post-quantum cryptographic security for blockchain systems.

Type III designs and manufactures mobility and communications hardware for demanding operational environments.

Ulysses develops autonomous maritime vehicles and software for subsea operations and infrastructure monitoring.

Vector develops autonomous defense systems and trains military users to deploy them at scale.

Alan Flores-Lopez is published by Neo as Lumos Co-Founder. This is a publicly listed external mentoring or applicant-interviewing affiliation, not an assertion of employment by Neo or a personal investment.

MatX designs processors optimized for training and running large language models.

Early-stage medical technology venture capital firm founded by Jenny Barba and Jeff Chu. Provides operational and technical support to medical-device companies. Led the Series A financing and spinout of Resonant Link Medical, which supplies wireless power for implantable devices and brain-computer interfaces.

Venture capital firm backing deep technology at the intersection of government demand and commercial markets. Led by Sherman Williams and Emily McMahan, with a network of service-academy graduates. Its healthcare investments include Resonant Link Medical’s implantable-device wireless power platform.

Early-stage life-sciences venture capital firm investing in biopharmaceuticals, medical devices, and digital health. Based in Chattanooga, Tennessee, with a satellite office in Research Triangle Park, North Carolina. Its neuroscience exposure includes Aurenar’s neuromodulation platform.

Computational neuroimaging company founded by Yale researchers. Its NAIO software combines multimodal brain imaging and AI to develop biomarkers and support CNS drug development. Acquired by Johnson & Johnson in 2024 according to investor exit disclosures; published standalone leadership is retained as historical company evidence.

Raymond W. Cohen is a medical-device executive and former Axonics co-founder and CEO. Sherpa Healthcare Partners appointed him venture partner in January 2025 following Axonics’ acquisition by Boston Scientific. His current Resonant Link Medical biography corroborates the Sherpa venture affiliation and identifies his board chair role there. Institutional investment amounts are not personal investments inferred from his board positions.

Neurotechnology company developing an ear-worn, non-invasive neuromodulation device for intensive-care patients. Its V-Link platform uses transauricular vagus nerve stimulation to address inflammatory complications. Clinical development is ongoing; therapeutic benefit and commercial approval are not inferred from the company’s claims.

Medical-device company developing wireless power and data transfer for implantable devices, including neurostimulators and brain-computer interfaces. Its Aurion WPT platform supports battery-free and rechargeable implants. Spun out of Resonant Link in 2025; predecessor financing is kept separate.

Swiss biocomputing company developing computing systems based on cultured biological neural networks. Its Neuroplatform provides remote access to neural experiments for researchers. Based in Vevey, Switzerland.

Biological computing company developing systems that connect cultured human neurons to silicon hardware. Its CL1 platform and Cortical Cloud support experiments in neural computation, drug discovery, and disease modeling. The team operates from Melbourne, Australia, with engineering and manufacturing in Malaysia.

Kaleida Capital invests in NeuroAI, where neuroscience, neural interfaces and artificial intelligence meet. Its focus includes brain-computer interfaces, neural data, neuromodulation, precision therapeutics and computing systems inspired by biological intelligence.

AI Stroke develops AI diagnostic software to help paramedics and frontline clinicians identify strokes and guide emergency treatment decisions.

Diagnoly develops real-time AI software that helps sonographers detect fetal abnormalities during ultrasound examinations.

Ground Effect Ventures invests from seed to growth in neurotechnology and medical devices that combine hardware, physiological signals and applied AI. Its partners support clinical validation, regulatory strategy and commercialization.

Inside Therapeutics makes microfluidic instruments that encapsulate therapeutic RNA in lipid nanoparticles for drug development and manufacturing.

Madison Scientific, Inc. (MadSci) is a Chicago medical-device developer working on smart electromechanical technology for neurological conditions. Its SmartShunt Hydrocephalus Management System combines a proprietary valve, intracranial-pressure sensing and control algorithms intended to personalize cerebrospinal-fluid drainage and support informed patient management. The device is under development and is not authorized for use or commercially available in any country; anticipated reductions in shunt failure and clinical benefits remain development objectives rather than established clinical performance. Neuroscience relevance comes from hydrocephalus and intracranial-pressure management; the issuer’s intelligent algorithms do not independently establish machine-learning use. Its current public directory lists four executives, seven board members and scientific, entrepreneurial and patient-family advisors. The March2025 $7M seed close expanded within the same offering: a September2025 announcement raised the aggregate target to $10M, and mHUB’s October9,2025 primary announcement subsequently confirmed the expanded $10M round had closed. These are milestones of one seed financing, rather than $17M in separate rounds.

NeuraWorx develops bioelectronic devices intended to improve cerebrovascular and glymphatic function.

Niremia Collective invests in early-stage wellbeing technology, including neuroscience, AI and digital health tools for mental, emotional and social health.

Piraeus Medical develops interventional devices for treating neurovascular conditions.

Raidium builds radiology foundation models and AI tools that help radiologists analyze medical images and produce diagnostic reports.

StimCardio Medical develops wearable neuromodulation that combines physiological sensing with personalized therapy, initially for atrial fibrillation.

Alex Amen is a biomedical scientist and PsyMed adviser with gene and cell therapy expertise. Her experience includes therapeutic asset acquisition and postdoctoral research in Jennifer Doudna’s laboratory.

Christopher Luzzio serves Madison Scientific as Co-Founder, Advisor. The company identifies him as a cofounder and neurologist associated with the University of Wisconsin School of Medicine and Public Health.

Chrystal Mavros is a PsyMed adviser. The firm describes her Columbia University microbiology work spanning gene therapy, the gut–brain relationship, sequencing and postmortem brain analysis.

Danny Carbonero is an investor and biomedical engineer with prior experience at Breakout Ventures. His Boston University doctoral research focused on computational neuroscience, and he helped lead Nucleate Boston.

David Hsu serves Madison Scientific as Co-Founder, Advisor. The company identifies him as a cofounder and professor of neurology associated with the University of Wisconsin–Madison.

Dina Burkitbayeva co-founded PsyMed Ventures. The firm also identifies her leadership of Freedom Biosciences, which develops neuropsychiatric therapeutics.

Medical-device engineer and investor who worked on core fund strategy and Series A through growth investments at Nexus NeuroTech Ventures. Now a general partner and co-founder at Ground Effect Ventures; previously led engineering at Deerfield Catalyst and Coridea.

Registered patent attorney and founder of Calyx Law, advising on intellectual property involving psychedelics and related technologies.

Greg Kubin co-founded PsyMed Ventures and co-hosts Business Trip. He previously co-founded HelloSponsor and worked at Morgan Stanley and Viacom.

Draig Therapeutics scientific advisory board member and Yale University professor and chair of psychiatry, with neuroscience and psychiatric drug development expertise.

Neurotechnology investor and engineer who built and led Nexus NeuroTech Ventures’ seed fund and incubator program. Now a general partner and co-founder at Ground Effect Ventures; previously held operations and product-development roles at Verily and Apple.

Former Nexus NeuroTech Ventures general partner and co-founder. Previously president of medical devices at Verily and a neuromodulation R&D leader at Boston Scientific; currently a trusted adviser at Ground Effect Ventures.

Josh Medow serves Madison Scientific as Co-Founder, Board Member. The current issuer directory confirms this role; an expanded professional biography is not published there.

Martina Galdos works on operations at PsyMed Ventures. Her experience spans startup operations, sales enablement and product marketing, with a focus on applying AI to operational workflows.

Michael Nagy serves Madison Scientific as Chief Technology Officer. The current issuer directory confirms this role; an expanded professional biography is not published there.

Negin Mokhtari was published as a Bioluminescence Ventures Partner who joined in2023. Her prior experience includes early biotechnology investing at Genoa Ventures, scientific and founding-team work in drug delivery and screening, and commercial operations at Freenome. She earned a doctorate in precision medicine/drug delivery at UC San Diego and an electrical-engineering degree at Minnesota. This BLV association is documented by primary2024 announcement and archived2024–25 roster; continuing2026 employment is unverified. Existing otherfirm roles remain intact.

Sandi Lam serves Madison Scientific as Advisor. The company biography describes her neurosurgery leadership and pediatric neurosurgery professorship at Northwestern University Feinberg School of Medicine; no separately dated institutional appointment is inferred.

Tim Gardner is a neuroscientist and PsyMed venture partner. The firm identifies his University of Oregon bioengineering leadership and his earlier work on Neuralink’s founding team.

Medical technology entrepreneur and investor. Madison Scientific's own leadership directory identifies Tyler Wanke, MD, MBA, MEM, as its president, CEO and cofounder. Northwestern Kellogg's October2026 speaker announcement identifies him separately as managing director of Dendrion Ventures. SEC filings name him executive of several Dendrion venture vehicles.

Budapest-based early-stage venture capital firm backing founders from Central and Eastern Europe and their diaspora. Leads and co-leads pre-seed and seed rounds in AI-native software, robotics, drones, cybersecurity, data infrastructure, defense and creative-industry technology. Its team supports companies in building products and expanding into global markets.